Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
- Jan 6, 2023
- 2 min read
Updated: Jan 29, 2023
Today's announcement marks the first TriNKET opt-in outside of oncology.
Dragonfly to receive a $25 million payment and is eligible to receive potential future milestones and royalties on net sales.
WALTHAM, Mass., Jan. 6, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today's announcement marks the first TriNKET opt-in outside of oncology.
"We are delighted that our research collaboration initiated with Dragonfly in July 2020 on multiple sclerosis and neuro-inflammation has rapidly produced novel TriNKET drug candidate molecules that may provide new treatment options for patients with neurological diseases" said Richard Hargreaves, Senior Vice President, Neuroscience, Bristol Myers Squibb.
"We believe this opt-in decision by Bristol Myers Squibb further validates our drug discovery platform," said Bill Haney, Dragonfly's CEO. "The ongoing clinical trials of six Dragonfly-developed drugs including our wholly owned solid tumor targeting TriNKETs DF1001 (HER2), now in Phase 2, DF9001 (EGFR), and our BMS-partnered novel IL12 cytokine, underscore the breadth of Dragonfly's portfolio of innovative therapeutics, and potential to help patients with hematological cancers, solid tumor cancers, autoimmune diseases, and neurological conditions."
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel bispecific antibody technology to harness the body's innate immune system to bring breakthrough treatments to patients. Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne Deconinck | anne@dragonflytx.com
This sixth TriNKET opt-in by Bristol Myers Squibb is incredibly exciting news, especially since it marks their first collaboration expanding beyond oncology into neuroinflammation and neurological conditions. Seeing successful, real-world biopharma partnerships scale like this provides phenomenal case studies for students who look for Help With Healthcare Assignments, as it perfectly illustrates how biotechnology platforms mature and how corporate collaborations can accelerate the discovery of innovative, breakthrough treatments.
Khi quan sát cách các nền tảng phát triển nội dung, mình thấy Bet88 link lựa chọn hướng mở rộng khá đồng đều giữa nhiều danh mục khác nhau. Từ game bài, bắn cá cho đến thể thao đều có khu vực riêng để người dùng dễ theo dõi. Ngoài ra, những tính năng cơ bản như hỗ trợ trực tuyến cũng được tích hợp khá trực quan. Điều mình chú ý không phải số lượng nội dung mà là cách các khu vực được kết nối với nhau. Nhìn tổng thể, hệ thống mang lại cảm giác khá mạch lạc.
Dragonfly Therapeutics announcing its sixth TriNKET opt-in with Bristol Myers Squibb is a strong signal of confidence in their innovative immunotherapy platform. Each new collaboration expands potential applications and validates the science behind their approach. It feels much like Slope game, where momentum builds with every successful move—staying balanced and focused ensures progress continues without losing pace.
Interesting news and a great example of how long-term biotech partnerships can keep expanding into new areas. For a bit of entertainment after reading updates like this, I like playing Stickman Hook —the simple swinging mechanics make it a fun and relaxing way to unwind.
The expansion of TriNKET immunotherapy beyond oncology is a really important step for the future of neurological treatment research. What stood out to me most is how modern biotech collaborations now rely heavily on team coordination and trust, almost like the social dynamics players experience in Among Us when every decision affects the outcome.